What did we learn at the AUA this year?

The annual meeting of the American Urological Association (AUA) is one at which a great deal of information is exchanged, but a lot of that information is of limited utility to patients. … READ MORE …

Germline genetic testing for men with prostate cancer

In this week’s Journal of Clinical Oncology, there is a full-text article in the “Comments and Controversies” section entitled … READ MORE …

Good news and less good news for OPKO Diagnostics

So first the “less good” news … READ MORE …

Back to basics: two useful articles to pass along

The Prostate Cancer Foundation posted two useful and basic articles on its blog site this December that may be useful resources for men concerned about their risk for or newly diagnosed with prostate cancer or monitoring their PSA over time (for any one of all sorts of possible reasons). … READ MORE …

The development of a “10-minute cancer test”: the Methylscape

By now, many readers have probably seen news reports coming out of Australia about the “possible medical breakthrough” of a rapid, highly accurate test that can be used to detect cancer anywhere in the body (prostate cancer specifically included). … READ MORE …

Medicare to cover costs of new test for AR-V7

We have recently learned that Medicare will be covering the costs of the Oncotype DX AR-V7 Nucleus Detect™ test for patients with metastatic, castration-resistant prostate cancer (mCRPC) as of December 10, 2018. … READ MORE …

Germline mutations and risk for advanced prostate cancer

Many people are increasingly interested in whether genetic testing can help them to understand their risk for cancer. The basic answer is that “Yes, it can.” However, what is also clear is that it is only going to be helpful for a small percentage of the population. … READ MORE …